GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biomerica Inc (NAS:BMRA) » Definitions » Return-on-Tangible-Asset

Biomerica (Biomerica) Return-on-Tangible-Asset : -70.54% (As of Feb. 2024)


View and export this data going back to 1978. Start your Free Trial

What is Biomerica Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Biomerica's annualized Net Income for the quarter that ended in Feb. 2024 was $-7.67 Mil. Biomerica's average total tangible assets for the quarter that ended in Feb. 2024 was $10.88 Mil. Therefore, Biomerica's annualized Return-on-Tangible-Asset for the quarter that ended in Feb. 2024 was -70.54%.

The historical rank and industry rank for Biomerica's Return-on-Tangible-Asset or its related term are showing as below:

BMRA' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -56.02   Med: -28   Max: -3.51
Current: -55.58

During the past 13 years, Biomerica's highest Return-on-Tangible-Asset was -3.51%. The lowest was -56.02%. And the median was -28.00%.

BMRA's Return-on-Tangible-Asset is ranked worse than
79.54% of 865 companies
in the Medical Devices & Instruments industry
Industry Median: -2.31 vs BMRA: -55.58

Biomerica Return-on-Tangible-Asset Historical Data

The historical data trend for Biomerica's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomerica Return-on-Tangible-Asset Chart

Biomerica Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -46.64 -24.09 -52.04 -39.87 -56.02

Biomerica Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -74.14 -64.16 -33.16 -48.92 -70.54

Competitive Comparison of Biomerica's Return-on-Tangible-Asset

For the Medical Devices subindustry, Biomerica's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomerica's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Biomerica's Return-on-Tangible-Asset falls into.



Biomerica Return-on-Tangible-Asset Calculation

Biomerica's annualized Return-on-Tangible-Asset for the fiscal year that ended in May. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: May. 2023 )  (A: May. 2022 )(A: May. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: May. 2023 )  (A: May. 2022 )(A: May. 2023 )
=-7.14/( (11.204+14.289)/ 2 )
=-7.14/12.7465
=-56.02 %

Biomerica's annualized Return-on-Tangible-Asset for the quarter that ended in Feb. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Feb. 2024 )  (Q: Nov. 2023 )(Q: Feb. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Feb. 2024 )  (Q: Nov. 2023 )(Q: Feb. 2024 )
=-7.672/( (11.627+10.126)/ 2 )
=-7.672/10.8765
=-70.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Feb. 2024) net income data.


Biomerica  (NAS:BMRA) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Biomerica Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Biomerica's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomerica (Biomerica) Business Description

Traded in Other Exchanges
N/A
Address
17571 Von Karman Avenue, Irvine, CA, USA, 92614
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.
Executives
John P. Kenny director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Zacharys Irani director, officer: Cheif Executive Officer 17571 VON KARMAN AVE., IRVINE CA 92614
Gary Lu officer: Chief Financial Officer 12136 AHERN CT, TUSTIN CA 92782
Allen Barbieri director
Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526
David Moatazedi director C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Steven Sloan officer: Chief Financial Officer 114 TERRAPIN, IRVINE CA 92618
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Francis Cano director 11 ACORN LANE, LOS ALTOS CA 94022
Francis E Capitanio officer: President-diagnostics 1533 MONROVIA AVENUE, NEWPORT BEACH CA 92663
Janet Moore director, 10 percent owner, officer: Secretary 1533 MUNROVIA AVE, NEWPORT BEACH CA 92663
Jane Emerson director 1533 MONROVIA AVE, NEWPORT BEACH CA 92663
William Snider other: Greater than 5% holder 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Broadoak Fund The other: Greater than 5% holder 7201 WISCONSIN AVE. #630, BETHESDA MD 20814
John Roehm director 1533 MONROVIA AVE., NEWPORT BEACH CA 92663